RMB Capital Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.9% during the first quarter, HoldingsChannel.com reports. The firm owned 61,573 shares of the company’s stock after buying an additional 1,731 shares during the quarter. RMB Capital Management LLC’s holdings in Johnson & Johnson were worth $7,891,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Peregrine Asset Advisers Inc. raised its stake in shares of Johnson & Johnson by 10.7% in the 4th quarter. Peregrine Asset Advisers Inc. now owns 4,018 shares of the company’s stock valued at $561,000 after acquiring an additional 387 shares during the period. Gardner Russo & Gardner LLC raised its stake in shares of Johnson & Johnson by 30.4% in the 1st quarter. Gardner Russo & Gardner LLC now owns 1,715 shares of the company’s stock valued at $220,000 after acquiring an additional 400 shares during the period. Spectrum Management Group Inc. raised its stake in shares of Johnson & Johnson by 2.8% in the 1st quarter. Spectrum Management Group Inc. now owns 14,841 shares of the company’s stock valued at $1,902,000 after acquiring an additional 410 shares during the period. Mountain Pacific Investment Advisers Inc. ID raised its stake in shares of Johnson & Johnson by 1.4% in the 1st quarter. Mountain Pacific Investment Advisers Inc. ID now owns 29,762 shares of the company’s stock valued at $3,814,000 after acquiring an additional 417 shares during the period. Finally, Hodges Capital Management Inc. raised its stake in shares of Johnson & Johnson by 0.8% in the 1st quarter. Hodges Capital Management Inc. now owns 54,284 shares of the company’s stock valued at $6,956,000 after acquiring an additional 417 shares during the period. 71.53% of the stock is currently owned by institutional investors.

Shares of JNJ opened at $134.95 on Friday. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.32. The company has a market cap of $360.37 billion, a P/E ratio of 17.22, a price-to-earnings-growth ratio of 2.05 and a beta of 0.73. The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The firm had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same period in the prior year, the firm earned $1.83 EPS. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. research analysts forecast that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a yield of 2.67%. The ex-dividend date is Monday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.22% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Jefferies Financial Group set a $145.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Credit Suisse Group set a $151.00 price target on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday, July 13th. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Finally, Sanford C. Bernstein started coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $142.34.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

See Also: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.